Assets Sold under Purchase Agreement, Revenue

No definition available.

Name:	scyx_AssetsSoldunderPurchaseAgreementRevenue
Namespace Prefix:	scyx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Deferred revenue recognition period.

+ References

No definition available.

+ Details

Name:	scyx_DeferredRevenueRecognitionPeriod
Namespace Prefix:	scyx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.A)
-URI http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735

+ Details

Name:	us-gaap_DeferredOfferingCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseAndServicesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.

+ References

+ Details

Name:	us-gaap_NontradeReceivablesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Cash received from licensees for license fees during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsidiarySaleOfStockLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=scyx_SalesAgreementProspectusMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	Aug. 31, 2013	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Subsidiary, Sale of Stock [Line Items]
Deferred offering costs		$ 335,000		$ 345,000
Upfront payment received	$ 1,500,000
Deferred revenue recognition period	70 months
Revenue recognized from upfront payments		100,000	$ 64,000
Revenue related to assets sold under purchase agreement		0
Other receivable due from R-Pharm		$ 252,000		$ 233,000
Sales Agreement
Subsidiary, Sale of Stock [Line Items]
Deferred offering costs			$ 100,000